指南与共识骨肌技术与安全PETMR

关于PET/MR用于骨骼转移瘤成像效用的国际专家意见声明

An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2021-02-22

该国际专家意见声明由核医学与放射学专家(包括来自13个主要PET/MR中心的专家)基于同行评议文献及主要研究机构的经验、实践和协议,评估PET/MR在骨骼转移瘤中的应用。声明认为,[18F]-FDG和非[18F]-FDG PET/MR在多种原发恶性肿瘤的骨转移评估中可能较PET/CT提供关键优势,并建议在高度怀疑骨转移或骨转移会影响患者管理时考虑使用PET/MR。

要点

  • 基于原发恶性肿瘤特征、临床高度怀疑及骨转移会影响患者管理时,应考虑PET/MR用于分期。
  • [18F]-FDG和非[18F]-FDG PET/MR在多种原发恶性肿瘤的骨转移评估中可能较PET/CT提供关键优势。
  • 应选择合适的肿瘤特异性放射性药物,并严格遵循PET和MR协议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use.

METHODS: We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered.

RESULTS: Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies.

CONCLUSION: PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Husseini JS, Amorim BJ, Torrado-Carvajal A, et al. An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. Eur J Nucl Med Mol Imaging. 2021. PMID: 33619599. doi:10.1007/s00259-021-05198-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。